HS
HighVista Strategies Portfolio holdings
AUM
$272M
This Quarter Return
+6.61%
1 Year Return
+24.34%
3 Year Return
+176.43%
5 Year Return
+271.23%
10 Year Return
+682.63%
AUM
$216M
AUM Growth
+$216M
(-1.1%)
Cap. Flow
-$7.11M
Cap. Flow
% of AUM
-3.29%
Top 10 Holdings %
Top 10 Hldgs %
35.07%
Holding
172
New
38
Increased
33
Reduced
47
Closed
40
Top Buys
| 1 |
Capri Holdings
CPRI
|
$4.09M |
| 2 |
SPLK
Splunk Inc
SPLK
|
$4.04M |
| 3 |
Structure Therapeutics
GPCR
|
$3.77M |
| 4 |
AMED
Amedisys
AMED
|
$3.67M |
| 5 |
IDEAYA Biosciences
IDYA
|
$3.42M |
Top Sells
| 1 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
$5.49M |
| 2 |
MoonLake Immunotherapeutics
MLTX
|
$3.99M |
| 3 |
BKI
Black Knight, Inc. Common Stock
BKI
|
$3.59M |
| 4 |
MMP
Magellan Midstream Partners, L.P.
MMP
|
$3.49M |
| 5 |
AJRD
Aerojet Rocketdyne Holdings, Inc.
AJRD
|
$3.38M |
Sector Composition
| 1 | Healthcare | 46.09% |
| 2 | Technology | 13.85% |
| 3 | Consumer Discretionary | 6.89% |
| 4 | Financials | 3.51% |
| 5 | Communication Services | 3.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
101
argenx
ARGX
$44.2B
| $525K | 0.24% |
1,067
-711
| -40% | -$350K |
|
102
Constellium
CSTM
$1.93B
| $524K | 0.24% |
28,794
-900
| -3% | -$16.4K |
|
103
89bio
ETNB
$1.37B
| $522K | 0.24% |
33,792
-9,847
| -23% | -$152K |
|
104
Ultragenyx Pharmaceutical
RARE
$3.04B
| $520K | 0.24% |
14,591
+7,265
| +99% | +$259K |
|
105
United Therapeutics
UTHR
$17.7B
| $519K | 0.24% |
2,299
+557
| +32% | +$126K |
|
106
Krystal Biotech
KRYS
$4.35B
| $509K | 0.24% |
4,392
+1,862
| +74% | +$216K |
|
107
Autoliv
ALV
$9.56B
| $506K | 0.23% |
5,244
-600
| -10% | -$57.9K |
|
108
Revolution Medicines
RVMD
$7.43B
| $498K | 0.23% |
+18,005
| New | +$498K |
|
|
ITCI
109
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $497K | 0.23% |
+9,545
| New | +$497K |
|
110
TKO Group
TKO
$15.3B
| $497K | 0.23% |
+5,907
| New | +$497K |
|
|
VRNA
111
Verona Pharma
VRNA
$9.18B
| $487K | 0.23% |
29,873
-4,154
| -12% | -$67.7K |
|
112
Amylyx Pharmaceuticals
AMLX
$877M
| $482K | 0.22% |
26,349
+12,601
| +92% | +$231K |
|
113
Celldex Therapeutics
CLDX
$1.57B
| $481K | 0.22% |
17,482
-7,260
| -29% | -$200K |
|
114
Galapagos
GLPG
$2.06B
| $472K | 0.22% |
+13,647
| New | +$472K |
|
115
Incyte
INCY
$17B
| $471K | 0.22% |
8,158
-2,721
| -25% | -$157K |
|
|
PNT
116
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $465K | 0.22% |
+69,744
| New | +$465K |
|
117
TAL Education Group
TAL
$6.34B
| $458K | 0.21% |
+50,300
| New | +$458K |
|
|
ALPN
118
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $456K | 0.21% |
39,861
-50,426
| -56% | -$577K |
|
119
Natera
NTRA
$23B
| $445K | 0.21% |
10,066
+2,811
| +39% | +$124K |
|
120
Madrigal Pharmaceuticals
MDGL
$9.7B
| $445K | 0.21% |
3,045
+249
| +9% | +$36.4K |
|
121
Prothena Corp
PRTA
$452M
| $444K | 0.21% |
9,195
+2,789
| +44% | +$135K |
|
122
Syndax Pharmaceuticals
SNDX
$1.39B
| $428K | 0.2% |
29,490
-4,086
| -12% | -$59.3K |
|
123
Geron
GERN
$893M
| $426K | 0.2% |
200,893
+78,189
| +64% | +$166K |
|
124
4D Molecular Therapeutics
FDMT
$302M
| $425K | 0.2% |
+33,419
| New | +$425K |
|
125
Vera Therapeutics
VERA
$1.47B
| $424K | 0.2% |
+30,902
| New | +$424K |
|